Pharmacoeconomics of novel pharmacotherapies in triple-negative breast cancer

References

• Financial Burden of Cancer Care. Available 2022 Dec 4 from https://progressreport.cancer.gov/after/economic_burden. .
   Google Scholar
• Breast cancer overtakes lung cancer in terms of number of new cancer cases worldwide. IARC showcases key research projects to address breast cancer. (n.d.). Available 2022 Dec 26 from https://www.iarc.who.int/wp-content/uploads/2021/02/pr294_E.pdf.
   Google Scholar
• Arnold M, Morgan E, Rumgay H, et al. Current and future burden of breast cancer: global statistics for 2020 and 2040. Breast. 2022;66:15–23. .
   PubMed Web of Science ®Google Scholar
• Trapani D, Ginsburg O, Fadelu T, et al. Global challenges and policy solutions in breast cancer control. Cancer Treat Rev. 2022;104:102339. .
   PubMedGoogle Scholar
• Yin L, Duan J-J, Bian X-W, et al. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 2020;22(1):61. DOI:10.1186/s13058-020-01296-5
   PubMed Web of Science ®Google Scholar
• Allison KH, Hammond MEH, Dowsett M, et al. Estrogen and progesterone receptor testing in breast cancer: aSCO/CAP guideline update. J Clin Oncol. 2020;38(12):1346–1366. DOI:10.1200/JCO.19.02309
   PubMed Web of Science ®Google Scholar
• Wolff AC, Hammond MEH, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25(1):118–145. DOI:10.1200/JCO.2006.09.2775
   PubMed Web of Science ®Google Scholar
• Ovcaricek T, Frkovic S, Matos E, et al. Triple negative breast cancer - prognostic factors and survival. Radiol Oncol. 2011;45(1).
   PubMedGoogle Scholar
• Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15):4429–4434. DOI:10.1158/1078-0432.CCR-06-3045
   PubMed Web of Science ®Google Scholar
• Trivers KF, Lund MJ, Porter PL, et al. The epidemiology of triple-negative breast cancer, including race. Cancer Causes & Control. 2009;20(7):1071–1082. DOI:10.1007/s10552-009-9331-1
   PubMed Web of Science ®Google Scholar
• Onarheim KH, Iversen JH, Bloom DE. Economic benefits of investing in women’s health: a systematic review. PLoS ONE. 2016;11(3):e0150120.
   PubMed Web of Science ®Google Scholar
• Berkowitz N, Gupta S, Silberman G. Estimates of the lifetime direct costs of treatment for metastatic breast cancer. Value Health. 2000;3(1):23–30.
   PubMedGoogle Scholar
• Brandão M, Morais S, Lopes-Conceição L, et al. Healthcare use and costs in early breast cancer: a patient-level data analysis according to stage and breast cancer subtype. ESMO Open. 2020;5(6):e000984. DOI:10.1136/esmoopen-2020-000984
   PubMedGoogle Scholar
• Skinner KE, Haiderali A, Huang M, et al. Assessing direct costs of treating metastatic triple-negative breast cancer in the USA. J Comp Eff Res. 2021;10(2):109–118. DOI:10.2217/cer-2020-0213
   PubMedGoogle Scholar
• Barron JJ, Quimbo R, Nikam PT, et al. Assessing the economic burden of breast cancer in a US managed care population. Breast Cancer Res Treat. 2008;109(2):367–377. DOI:10.1007/s10549-007-9650-4
   PubMed Web of Science ®Google Scholar
• Zhuo J, Wu E, Dasbach E, et al. Cancer associated medical spending: US national data between 2000 and 2013. Value Health. 2016;19(7):A742–743. DOI:10.1016/j.jval.2016.09.2263
   Google Scholar
• Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379(22):2108–2121. DOI:10.1056/NEJMoa1809615
   PubMed Web of Science ®Google Scholar
• Miles D, Gligorov J, André F, et al. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. Ann Oncol. 2021;32(8):994–1004. DOI:10.1016/j.annonc.2021.05.801
   PubMed Web of Science ®Google Scholar
• Cortes J, Rugo HS, Cescon DW, et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N Engl J Med. 2022;387(3):217–226. DOI:10.1056/NEJMoa2202809
   PubMed Web of Science ®Google Scholar
• Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382(9):810–821. DOI:10.1056/NEJMoa1910549
   PubMed Web of Science ®Google Scholar
• Schmid P, Cortes J, Dent R, et al. Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med. 2022;386(6):556–567. DOI:10.1056/NEJMoa2112651
   PubMed Web of Science ®Google Scholar
• Robson M, Im S-A, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377(6):523–533. DOI:10.1056/NEJMoa1706450
   PubMed Web of Science ®Google Scholar
• Litton JK, Rugo HS, Ettl J, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018;379(8):753–763. DOI:10.1056/NEJMoa1802905
   PubMed Web of Science ®Google Scholar
• Geyer CE, Garber JE, Gelber RD, et al. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Ann Oncol. 2022;33(12):1250–1268. DOI:10.1016/j.annonc.2022.09.159
   PubMed Web of Science ®Google Scholar
• Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;384(16):1529–1541. DOI:10.1056/NEJMoa2028485
   PubMed Web of Science ®Google Scholar
• Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387(1):9–20. DOI:10.1056/NEJMoa2203690
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Available 2022 Dec 16 from https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-atezolizumab-pd-l1-positive-unresectable-locally-advanced-or-metastatic-triple-negative.
   Google Scholar
• EMA recommends extension of indications for atezolizumab. ESMO. Avaible 2022 Dec 26 from https://www.esmo.org/oncology-news/ema-recommends-extension-of-indications-for-atezolizumab.
   Google Scholar
• Genentech withdraws breast cancer indication from Tecentriq. Available 2022 Dec 24 from https://www.breastcancer.org/research-news/genentech-withdraws-breast-cancer-indication-from-tecentriq.
   Google Scholar
• Tecentriq. European medicines agency. Available 2022 Dec 24 from https://www.ema.europa.eu/en/medicines/human/EPAR/tecentriq.
   Google Scholar
• FDA grants accelerated approval to pembrolizumab for locally recurrent unresectable or metastatic triple negative breast cancer. U.S. Food and Drug Administration. Available 2022 Dec 24 from https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pembrolizumab-locally-recurrent-unresectable-or-metastatic-triple.
   Google Scholar
• EMA recommends extension of indications for Pembrolizumab. Avalable 2022 Dec 16 from https://www.esmo.org/oncology-news/ema-recommends-extension-of-indications-for-pembrolizumab6.
   Google Scholar
• Breast Cancer - NCCN. Available 2022 Dec 24 from https://www.nccn.org/professionals/physician_gls/pdf/breast.
   Google Scholar
• Gennari A, André F, Barrios CH, et al. ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021;32(12):1475–1495. DOI:10.1016/j.annonc.2021.09.019
   PubMed Web of Science ®Google Scholar
• FDA approves pembrolizumab for high-risk early-stage triple-negative Breast cancer. Available 2022 Dec 16 from https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-high-risk-early-stage-triple-negative-breast-cancer.
   Google Scholar
• Ema. (Keytruda. European Medicines Agency. Available 2022 Dec 16 from https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda.
   Google Scholar
• FDA approves Olaparib for adjuvant treatment of high-risk early breast cancer. U.S. Food and Drug Administration. Available Dec 24 2022 from https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-adjuvant-treatment-high-risk-early-breast-cancer.
   Google Scholar
• EMA recommends extension of therapeutic indications for Olaparib. ESMO. Available Dec 24 2022 from https://www.esmo.org/oncology-news/ema-recommends-extension-of-therapeutic-indications-for-olaparib.
   Google Scholar
• Nicolò E, Repetto M, Boscolo Bielo L, et al. Antibody-drug conjugates in breast cancer: what is beyond HER2? Cancer J. 2022;28(6):436–445. DOI:10.1097/PPO.0000000000000629
   PubMed Web of Science ®Google Scholar
• FDA grants regular approval to sacituzumab govitecan for triple-negative breast cancer. U.S. Food and Drug Administration. Available Dec 24 2022 from https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-regular-approval-sacituzumab-govitecan-triple-negative-breast-cancer.
   Google Scholar
• Ema. (2022, Jul 12). Trodelvy. European Medicines Agency. Available Dec 24, 2022 from http://www.ema.europa.eu/en/medicines/human/EPAR/trodelvy.
   Google Scholar
• Food and drug administration. TRODELVY®. Available Dec 24 2022 from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761115s009lbl.pdf.
   Google Scholar
• Trodelvy. European Medicines Agency. Retrieved Dec 24, 2022, from https://www.ema.europa.eu/en/medicines/human/EPAR/trodelvy.
   Google Scholar
• FDA approves fam-trastuzumab deruxtecan-nxki for HER2-low breast cancer. U.S. Food and Drug Administration. Available Dec 24 2022 from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-fam-trastuzumab-deruxtecan-nxki-her2-low-breast-cancer.
   Google Scholar
• ENHERTU recommended for approval in the EU by CHMP for patients with HER2-low metastatic breast cancer. Available Dec 24 2022 from: https://www.astrazeneca.com/media-centre/press-releases/2022/enhertu-recommended-for-eu-approval-in-her2-low-bc.html.
   Google Scholar
• Wu B, Ma F. Cost-effectiveness of adding atezolizumab to first-line chemotherapy in patients with advanced triple-negative breast cancer. Ther Adv Med Oncol. 2020;12:175883592091600.
   Web of Science ®Google Scholar
• Li J, Zhang T, Lu P, et al. Cost–effectiveness analysis of atezolizumab plus nab-paclitaxel for untreated metastatic triple-negative breast cancer. Immunotherapy. 2020;12(10):705–713. DOI:10.2217/imt-2020-0036
   PubMedGoogle Scholar
• Chisaki Y, Kuwada Y, Matsumura C, et al. Cost-effectiveness analysis of atezolizumab plus nab-paclitaxel for advanced PD-L1 positive triple-negative breast cancer in Japan. Clin Drug Investig. 2021;41(4):381–389. DOI:10.1007/s40261-021-01017-6
   PubMedGoogle Scholar
• Liu X, Lang Y, Liao Y, et al. Atezolizumab plus chemotherapy vs. chemotherapy in advanced or metastatic triple-negative breast cancer: a cost-effectiveness analysis. Front Public Health. 2021;9. DOI:10.3389/fpubh.2021.756899
   Google Scholar
• Weng X, Huang X, Li H, et al. First-line treatment with atezolizumab plus nab-paclitaxel for advanced triple-negative breast cancer. Am J Clin Oncol. 2020;43(5):340–348. DOI:10.1097/COC.0000000000000671
   PubMed Web of Science ®Google Scholar
• Phua LC, Lee SC, Ng K, et al. Cost-effectiveness analysis of atezolizumab in advanced triple-negative breast cancer. BMC Health Serv Res. 2020;20(1):581. DOI:10.1186/s12913-020-05445-6
   PubMed Web of Science ®Google Scholar
• Huang M, Fasching P, Haiderali A, et al. Cost–effectiveness of pembrolizumab plus chemotherapy as first-line treatment in PD-L1-positive metastatic triple-negative breast cancer. Immunotherapy. 2022;14(13):1027–1041. DOI:10.2217/imt-2022-0082
   PubMedGoogle Scholar
• Fasching PA, Huang M, Haiderali A, et al. 99P cost effectiveness of pembrolizumab in combination with chemotherapy as neoadjuvant therapy and continued as a single agent as adjuvant therapy for high-risk early-stage TNBC in the United States. Ann Oncol. 2022;33:S170–171.
   Google Scholar
• Saito S, Nakazawa K, Nagahashi M, et al. Cost–effectiveness of BRCA1/2 mutation profiling to target olaparib use in patients with metastatic breast cancer. Per Med. 2019;16(6):439–448. DOI:10.2217/pme-2018-0141
   PubMed Web of Science ®Google Scholar
• de Labry Lima AO, Špacírová Z, Fénix-Caballero S, et al. Cost-utility of talazoparib monotherapy treatment for locally advanced or metastatic breast cancer in Spain. Breast. 2021;58:27–33.
   PubMedGoogle Scholar
• Schwarz F, Arefian H, Hartmann M, et al. Cost-effectiveness of talazoparib for patients with locally advanced or metastasized breast cancer in Germany. PLoS ONE. 2022;17(12):e0278460. DOI:10.1371/journal.pone.0278460
   PubMedGoogle Scholar
• Zettler C, De Silva D, Blinder VS, et al. Cost effectiveness of adjuvant olaparib for BRCA-mutated, early-stage breast cancer. J Clin Oncol. 2022;40(16_suppl):6593. DOI:10.1200/JCO.2022.40.16_suppl.6593
   Google Scholar
• Chen J, Han M, Liu A, et al. Economic evaluation of sacituzumab govitecan for the treatment of metastatic triple-negative breast cancer in China and the US. Front Oncol. 2021;11:11.
   Google Scholar
• Lang Y, Wu B, Liu X. Economic evaluation of trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer in the United States. Breast Cancer: Target Therapy. 2022;14:453–463.
   PubMed Web of Science ®Google Scholar
• Giuliani J, Mantoan B, Bonetti A. The cost-effectiveness of atezolizumab in first-line for metastatic triple negative breast cancer is heavily linked to PD-L1 level. J Oncol Pharm Pract. 2021;27(5):1245–1247.
   PubMedGoogle Scholar
• Haiderali A, Huang M, Pan W, et al. HSR22-145: pembrolizumab plus chemotherapy for first-line treatment of advanced triple-negative breast cancer – a network meta-analysis. J National Compr Cancer Network. 2022;20(3.5):HSR22–145. DOI:10.6004/jnccn.2021.7297
   Google Scholar
• McCrea C, MacDonald D, Hettle R, et al. PCN207 COST COMPARISON of ADVERSE EVENT MANAGEMENT with POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS or CHEMOTHERAPY in GBRCA-MUTATED, HER2-NEGATIVE ADVANCED BREAST CANCER (ABC): a US and GERMAN HEALTHCARE PERSPECTIVE. Value Health. 2019;22:S476.
   Google Scholar
• Hurvitz SA, Tolaney SM, Punie K, et al. Biomarker evaluation in the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. 2020 san antonio breast cancer symposium. Abstract. 2020 Dec 10;81(4_Supplement):GS3–06. Presented. DOI:10.1158/1538-7445.SABCS20-GS3-06
   Google Scholar
• Huang M, Haiderali A, Fox GE, et al. Economic and humanistic burden of triple-negative breast cancer: a systematic literature review. Pharmacoeconomics. 2022;40(5):519–558. DOI:10.1007/s40273-021-01121-7
   PubMed Web of Science ®Google Scholar
• Cherny NI, Dafni U, Bogaerts J, et al. ESMO-Magnitude of clinical benefit scale version 1.1. Ann Oncol. 2017;28(10):2340–2366. DOI:10.1093/annonc/mdx310
   PubMed Web of Science ®Google Scholar
• Brezden-Masley C, Fathers KE, Coombes ME, et al. A population-based comparison of treatment patterns, resource utilization, and costs by cancer stage for Ontario patients with hormone receptor-positive/HER2-negative breast cancer. Breast Cancer Res Treat. 2021;185(2):507–515. DOI:10.1007/s10549-020-05960-4
   PubMedGoogle Scholar
• Michaeli DT, Michaeli T. Overall Survival, progression-free survival, and tumor response benefit supporting initial US food and drug administration approval and indication extension of new cancer drugs, 2003-2021. J Clin Oncol. 2022;40(35):4095–4106.
   PubMed Web of Science ®Google Scholar
• Litton JK, Hurvitz SA, Mina LA, et al. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Ann Oncol. 2020;31(11):1526–1535. DOI:10.1016/j.annonc.2020.08.2098
   PubMed Web of Science ®Google Scholar
• Loibl S, Loirat D, Tolaney SM, et al. Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer. Eur J Cancer. 2023;178:23–33.
   PubMed Web of Science ®Google Scholar
• Trapani D, Tay-Teo K, Tesch ME, et al. Implications of Oncology Trial Design and Uncertainties in Efficacy-Safety Data on Health Technology Assessments. Current Oncol. 2022;29(8):5774–5791. DOI:10.3390/curroncol29080455
   PubMedGoogle Scholar
• Alkhatib NS, Abraham I. The six delta platform for outcome-based contracting for pharmaceuticals. J Med Econ. 2020;23(11):1209–1214.
   PubMed Web of Science ®Google Scholar